← Back to Investors

TPG Biotech

TPG Biotech is the life sciences investment platform within TPG, one of the world's largest alternative asset managers with over $220 billion in AUM. The platform focuses on innovative biotechnology and healthcare companies across therapeutics, diagnostics, and healthcare technology.

Location
San Francisco, California, USA
Founded
2019
AUM
$6B+ (healthcare platform)
Investment Range
$50M - $500M
Portfolio Companies
1
Focus
biotech-focused
Fund Stages
series-b, series-c, growth

Investment Thesis

TPG Biotech invests in leading biotechnology and healthcare companies with differentiated science, experienced management teams, and large market opportunities. They leverage TPG's global resources and operational expertise to help portfolio companies scale. The platform focuses on growth-stage investments where they can provide significant capital and strategic value.

Team

Partners / Managing Directors

  • Jim Coulter - Co-Founder & Executive Chairman, TPG
  • Jon Winkelried - CEO, TPG
  • Todd Sisitsky - President, TPG

Healthcare/Biotech Team

  • Ravi Sarin - Partner, Healthcare
  • Matthew Hobart - Partner, Healthcare

Focus Areas

  • Biotechnology
  • Biopharma
  • Healthcare Technology
  • Diagnostics
  • Healthcare Services
  • Life Sciences Tools

Notable Portfolio Companies

  • DNAnexus - Cloud-based genomics data platform
  • Tempus - AI-enabled precision medicine
  • Exact Sciences - Cancer diagnostics
  • Precision BioSciences - Gene editing
  • Sutro Biopharma - Cell-free protein synthesis

Notable Exits

  • Cepheid - Acquired (2016, acquired by Danaher for $4B)
  • PAREXEL - Taken private (2017, $5B deal)
  • Envision Healthcare - Taken private (2018, $9.9B deal)
  • Multiple healthcare portfolio company IPOs

Sources

Portfolio Companies

NameLocationFoundedCategories
DNAnexusMountain View, California, USA2009
genomicscloud-platform+3